Volksbank Lüneburger Heide eG

Bitte mindestens 3 Zeichen eingeben.

Factsheet

B.R.A.I.N. BIOTECHNOLOGY AG NAMENS-AKTIEN O.N.

Hinweis

Sie erhalten zu diesem und zukünftigen Kursalarmen
nur eine E-Mail Benachrichtigung, wenn Sie zum Zeitpunkt
des Auslösens eine E-Mail Adresse hinterlegt und diese
bestätigt haben.

E-Mail Adresse

Notiz hinzufügen

dpa-AFX: DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH (english)

25.06.2019 - 12:41:08
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells
its entire stake in Monteil Cosmetics International GmbH

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Disposal
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells
its entire stake in Monteil Cosmetics International GmbH

25.06.2019 / 12:40
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Focus on B2B-business

BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH

  * BRAIN thereby withdraws from the loss-making segment of the B2C
    cosmetics business


  * Focus on growth in the product-scalable B2B product business of the
    BRAIN Group



Zwingenberg, Germany
25 June 2019

BRAIN AG (together with its subsidiaries the "BRAIN Group" or "BRAIN") has
concluded an agreement with Wilde Cosmetics GmbH, Oestrich-Winkel, on the
sale of all shares in the loss-making Monteil Cosmetics International GmbH
("Monteil") held by BRAIN to Wilde Cosmetics GmbH. The transaction will be
completed on 30 June 2019. The contracting parties have agreed not to
disclose financial details.

Monteil Cosmetics International GmbH, based in Düsseldorf, is represented as
a brand company in the cosmetics end customer business (B2C). It has been
part of the BRAIN Group since 2011. Most recently, BRAIN AG held 68.3% of
the Monteil shares, while Wilde Cosmetics GmbH acted as a minority
shareholder. The sale of the loss-making investment will unburden the BRAIN
Group both financially and in terms of capacity and allow it to concentrate
fully on the further expansion of the product-scalable B2B business.

"The focus of the BRAIN Group is on growing the product business with
industrial partners. The companies in the BRAIN Group are now fully
specialized in R&D and B2B business. This is where we see the absolute
strengths of the BRAIN Group, which we are continuously expanding", says Dr.
Jürgen Eck, CEO of BRAIN AG.

"We have taken a further step towards consistently implementing our
strategy. The pure B2B cosmetics business is and will remain part of the
growth strategy", says Ludger Roedder, CBO of BRAIN AG.

"The sale of the Monteil shares has no impact on the forecasts of BRAIN AG
for the current 2018/19 financial year. Rather, we confirm the objective of
achieving a double-digit growth rate in total operating performance and
improved EBITDA at Group level", adds Manfred Bender, CFO of BRAIN AG.

+++END+++

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN
DE0005203947 / WKN 520394) is one of Europe's leading technology companies
in the field of industrial biotechnology, the core discipline of Bioeconomy.
As such, BRAIN identifies previously untapped, efficient enzymes, microbial
producer organisms or natural substances from complex biological systems
that can be put to industrial use. The innovative solutions and products
developed by help of this "Toolbox of Nature" are successfully applied in
the chemistry, the cosmetics and the food industries. BRAIN's business model
is based on two pillars. The BioScience segment comprises mainly of the
research and development business with industrial partners (the "Tailor-Made
Solutions" cooperation business), and the company's own research and
development. The BioIndustrial segment consists mainly of the industrially
scalable products business. Further information is available at
www.brain-biotech.de/en.


BRAIN

Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.de

Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: ir@brain-biotech.de


Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAIN
AG and the BRAIN group of companies. Such factors include, but are not
limited to, changes in the general economic and competitive environment,
risks associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. BRAIN AG does
not undertake any obligation to update or revise any forward-looking
statements.


---------------------------------------------------------------------------

25.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:       English
   Company:        B.R.A.I.N. Biotechnology Research And Information
                   Network AG
                   Darmstädter Straße 34-36
                   64673 Zwingenberg
                   Germany
   Phone:          +49 (0) 62 51 / 9331-0
   Fax:            +49 (0) 62 51 / 9331-11
   E-mail:         ir@brain-biotech.de
   Internet:       www.brain-biotech.de
   ISIN:           DE0005203947
   WKN:            520394
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    830387




End of News DGAP News Service
---------------------------------------------------------------------------

830387 25.06.2019

Bezeichnung
WKN
Börse
Kurs
Währung
±
±%
Kurs vom
B.R.A.I.N. NA 520394
Frankfurt
9,660
EUR
+0,06
+0,62%
26.06.19
17:25:09
Zeit Meldung
25.06.
dpa-AFX: DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH (english)
25.06.
dpa-AFX: DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG veräußert sämtliche Anteile an der Monteil Cosmetics International GmbH (deutsch)
25.06.
dpa-AFX: DGAP-Adhoc: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG veräußert ihren Mehrheitsanteil an der Monteil Cosmetic International GmbH (deutsch)
25.06.
dpa-AFX: DGAP-Adhoc: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells its majority stake in Monteil Cosmetic International GmbH (english)
12.06.
dpa-AFX: *DEUTSCHE BANK NIMMT WIRECARD UND BRAIN BIOTECH IN 'GERMAN STOCK IDEAS' AUF
29.05.
dpa-AFX: DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG verzeichnet deutliches Wachstum im ersten Halbjahr des Geschäftsjahres 2018/19 (deutsch)
29.05.
dpa-AFX: DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG achieves significant growth in the first half of the 2018/19 financial year (english)
14.03.
dpa-AFX: DGAP-DD: B.R.A.I.N. Biotechnology Research And Information Network AG (deutsch)
14.03.
dpa-AFX: DGAP-DD: B.R.A.I.N. Biotechnology Research And Information Network AG (english)
13.03.
dpa-AFX: DGAP-DD: B.R.A.I.N. Biotechnology Research And Information Network AG (english)
Seitenanfang